Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Callispheres D-TACE for Advanced Breast Cancer
ChiCTR2100051017Phase 4Recruiting
- Sponsor
- Suining Central Hospital
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epirubicin in breast cancer, sponsored by Suining Central Hospital. Primary endpoints: Objective response rate and Disease control rate. Started Sep 2021; status: recruiting.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100051017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051017.